Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132.

Authors

D. Wang

Medical College of Wisconsin, Milwaukee, WI

D. Wang , Q. Zhang , C. D. Blanke , G. D. Demetri , M. C. Heinrich , J. C. Watson , J. P. Hoffman , S. H. Okuno , J. M. Kane , M. vonMehren , B. L. Eisenberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).

First Author: Desmond Yip

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST).

First Author: M. von Mehren

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

The overall survival analysis of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer—An open-label, single-arm, phase 2 trial.

First Author: Li Chen

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study.

First Author: Jonathan C. Trent